Shekhar, Shefali Chowdhary, Joel Mosnier, Isabelle Fonta, Bruno Pradines and Vipan Kumar
{"title":"Design, synthesis and mechanistic insights into triclosan derived dimers as potential anti-plasmodials†","authors":"Shekhar, Shefali Chowdhary, Joel Mosnier, Isabelle Fonta, Bruno Pradines and Vipan Kumar","doi":"10.1039/D4MD00494A","DOIUrl":null,"url":null,"abstract":"<p >In pursuit of novel anti-plasmodial agents, a library of triclosan-based dimers both with and without a 1<em>H</em>-1,2,3 triazole core were designed and synthesized in order to achieve a multitargeted approach. <em>In vitro</em> assessment against chloroquine-susceptible (3D7) and resistant (W2) <em>P. falciparum</em> strains identified that two of the synthesized dimers containing triazole were the most potent in the series. The most potent of the synthesized compounds exhibited IC<small><sub>50</sub></small> values of 9.27 and 12.09 μM against the CQ-resistant (W2) and CQ-susceptible (3D7) strains of <em>P. falciparum</em>, with an RI of 0.77, suggesting little or no cross-resistance with CQ. Heme binding and molecular modelling studies revealed the most promising scaffold as a dual inhibitor for hemozoin formation and a <em>P. falciparum</em> chloroquine resistance transporter (<em>Pf</em>CRT), respectively. <em>In silico</em> studies of the most potent compound revealed that it shows better binding affinity with <em>Pf</em>ACP and <em>Pf</em>CRT compared to TCS. To the best of our knowledge, this is the first report of triclosan-based compounds demonstrating promising heme-inhibition behaviour, with binding values comparable to those of chloroquine (CQ).</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 2","pages":" 709-720"},"PeriodicalIF":3.5970,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00494a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
In pursuit of novel anti-plasmodial agents, a library of triclosan-based dimers both with and without a 1H-1,2,3 triazole core were designed and synthesized in order to achieve a multitargeted approach. In vitro assessment against chloroquine-susceptible (3D7) and resistant (W2) P. falciparum strains identified that two of the synthesized dimers containing triazole were the most potent in the series. The most potent of the synthesized compounds exhibited IC50 values of 9.27 and 12.09 μM against the CQ-resistant (W2) and CQ-susceptible (3D7) strains of P. falciparum, with an RI of 0.77, suggesting little or no cross-resistance with CQ. Heme binding and molecular modelling studies revealed the most promising scaffold as a dual inhibitor for hemozoin formation and a P. falciparum chloroquine resistance transporter (PfCRT), respectively. In silico studies of the most potent compound revealed that it shows better binding affinity with PfACP and PfCRT compared to TCS. To the best of our knowledge, this is the first report of triclosan-based compounds demonstrating promising heme-inhibition behaviour, with binding values comparable to those of chloroquine (CQ).
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.